51 min
Episode 23. Bispecific Antibodies in Myeloma Blood Cancer Talks
-
- Education
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:
1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/
2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619
3. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/
4. Phase 1 trial of fixed-duration cevostamab:
https://ashpublications.org/blood/article/140/Supplement%201/4415/492339
5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/
6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/
In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:
1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/
2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619
3. Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/
4. Phase 1 trial of fixed-duration cevostamab:
https://ashpublications.org/blood/article/140/Supplement%201/4415/492339
5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/
6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/
51 min